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Abstract 
Death  Receptors  (DR)  selectively  drive  cancer  cells  to  apoptosis  upon binding to  the 
Tumor necrosis factor--Related Apoptosis-Inducing Ligand (TRAIL). Complex formation 
induces the oligomerization of the death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) 
and  transduces  the  apoptogenic  signal  to  their  respective  Death  Domains,  leading  to 
Death Inducing Signaling Complex (DISC) formation, caspase activation and ultimately 
cell death. Several crystal structures of the ExtraCellular Domain from Death Receptor 5 
(DR5-ECD) have been reported in complex with the TRAIL ligand or anti-DR5 antibodies, 
but  none  for  the  isolated  protein.  In  order  to  fill  this  gap  and  to  perform  binding 
experiments with TRAIL peptidomimetics,  we have produced isotopically labelled DR5-
ECD and started a conformational  analysis by using high-field 3D NMR spectroscopy.  
Herein, we present the first resonance assignment of a TRAIL receptor in solution and the 
determination of its secondary structure from NMR chemical shifts.
Abbreviations:  DR5  Death  Receptor  5;  TRAIL  Tumor  necrosis  factor--Related 
Apoptosis-Inducing  Ligand;  ECD  Extra  Cellular  Domain;  HSQC  Heteronuclear  Single 
Quantum Coherence transfer.
Keywords: DR5; TRAIL; Cancer; Apoptosis; NMR spectroscopy; Resonance Assignment; 
Secondary Structure.
Biological context
Tumor necrosis factor--Related Apoptosis-Inducing Ligand (TRAIL/Apo2L/TNFSF10) is a 
type II transmembrane trimeric protein that induces apoptosis of cancer cells while sparing 
normal ones (Ashkenazi A and Dixit VM, 2008). Four membrane-bound TRAIL specific 
receptors  have  been  described,  comprising  two  Death  Receptors 
(DR4/TNFRSF10A/TRAIL-R1  and  DR5/TNFRSF10B/TRAIL-R2)  that  mediate  the 
apoptogenic  signal  and  two  Decoy  Receptors  (DcR1/TNFRSF10C/TRAIL-R3  and 
DcR2/TNFRSF10D/TRAIL-R4) that bind the ligand but do not transduce the apoptogenic  
signal (MacFarlane M et al, 1997; Walczak H et al, 1997). TRAIL binding induces receptor 
oligomerization (Ashkenazi A et Dixit VM, 1998), transduction of the apoptogenic signal to 
the intracellular death domain (DD) of the receptors and DISC formation. Autocleavage of 
the  initiator  caspases  results  in  activation  of  the  death-executing  caspase  cascade, 
leading to  cell  death (Ashkenazi  A and Dixit  VM, 2008;  Newsom-Davis T et  al,  2009; 
Takeda  K  et  al,  Oncogene  2007;  Merino  D  et  al,  2007)  Crystal  structures  of  TRAIL  
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complexed with the Extra Cellular Domain (residues 6-135 of  our plasmid construct) of  
DR5 (DR5-ECD) unravel the mechanism for receptor oligomerization (Hymowitz SG et al,  
1999:  1DOG.pdb;  Mongkolsapaya  J  et  al,  1999:  1D4V.pdb;  Cha  SS  et  al,  2000: 
1DU3.pdb):  The elongated DR5 receptors snuggle into long crevices between pairs of 
monomers of the homotrimeric TRAIL ligand, but do not interact with each other.  The  
TRAIL/DR5 interface  is  divided  into  two distinct  patches,  one  near  the  bottom of  the  
complex close to the membrane surface (90S loop of DR5) and one near the top (50S  
loop of DR5). The elongated structure of DR5-ECD is arranged into three Cysteine-Rich 
Domains (CRD). CRD1 (32-48) adopts a beta hairpin conformation (B1B2) stabilized by 
the disulphide bridge 33-46 and is  preceded by the N-terminal  region in  a disordered 
conformation. CRD2 (49-90) and CRD3 (91-135) possess two consecutive beta hairpins 
(B3-B6 and B7-B10 respectively) stabilized by three disulphide bridges (49-65, 68-81, 71-
89 and 91-105, 108-122, 112-130 respectively). The 50S loop (residues S56 to R67) and 
90S loop (residues E99 to R109) involved in TRAIL binding display similar conformations 
despite the absence of any sequence homology. The crystal structure of DR5-ECD has 
also been solved in complex with the human glycoprotein UL141 (Nemčovičova I et al, 
2013: 4I9X.pdb) and with the Fab fragments of five anti-DR5 antibodies (Fellouse FA et al,  
2005: 1ZA3.pdb; Li B et al, 2006: 2H9G.pdb; Adams C et al, 2008: 4OD2.pdb; Graves JD 
et al, 2014: 4N90.pdb; Tamada J et al, 2015: 3X3F.pdb). No structural characterization of  
the  isolated  DR5-ECD  has  yet  been  reported  either  by  crystallography  or  NMR 
spectroscopy.
We report here for the first time the assignment of NMR resonances and the secondary 
structure determination of a TRAIL Death Receptor in solution, namely DR5/TRAIL-R2.  
Chemical  shift  assignment  has  been  used  to  perform binding  studies  with  TRAILmim 
peptidomimetics that bind to DR5 (Pavet V et al, 2010; Pulka-Ziach K et al, 2015; Beyrath 
J et al, 2016) and the results will be reported in a future publication.
Materials and Experiments:
Sample preparation
The  DR5  extracellular  domain  (DR5-ECD)  was  cloned  from  a  commercial  pET23m 
plasmid containing the DR5 gene (Hye-Ji CHI,  2010) by using PCR amplification. The 
primers were designed to introduce NcoI and BamHI restriction sites, respectively, in order 
to insert the gene into a modified pET23-d plasmid containing an N-terminal Histidine (6)-
tag followed by E. coli NusA protein and a tobacco etch virus (TEV) cleavage site. Correct 
cloning was confirmed by DNA sequencing. The production of the protein was carried out 
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by heat-shock transformation of the plasmid in BL21(DE3) E. coli bacteria (New England 
Biolabs),  which were then cultured in 1 L of  15N/13C,15N enriched minimal M9 medium, 
containing  1  g/L of  13C15N Isogro® (Sigma Aldrich).  Following bacteria  growth,  protein 
expression  was  induced  at  a  bacterial  OD600nm of  0.8  with  isopropyl  β-D-1-
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM, for 16 hours at 25 °C. 
The cells were then harvested by centrifugation and stored at -80°C. All purification steps 
were  carried  out  with  Fast  Protein  Liquid  Chromatography  (FPLC)  on  an  AKTA Pure 
system (GE Healthcare). Cell pellets were thawed and resuspended in lysis buffer (50 mM 
Tris pH 7.5, 500 mM NaCl,  5 mM imidazole),  in the presence of  phenylmethylsulfonyl 
fluoride (PMSF) as a protease inhibitor,  followed by cell  lysis performed by sonication. 
Membranes and cell debris were centrifuged, and the supernatant was loaded on a 5 mL  
HisTrap HP column (GE Healthcare),  previously  equilibrated  with  the  lysis  buffer.  The 
column was then washed with 10 column volumes of washing buffer (50 mM Tris pH 7.5,  
500 mM NaCl, imidazole 25mM), and protein was eluted with a 50 mM Tris pH 7.5, 500 
mM NaCl, imidazole 300mM buffer. Purity of the sample was enhanced by a step of size 
exclusion chromatography on a HiLoad 16/600 Superdex 200 prep grade column (GE 
Healthcare), previously equilibrated with appropriate buffer (20 mM Tris pH 7.8, 50 mM 
NaCl). TEV protease cleavage was then carried out overnight at room temperature, at a 
TEV:NusA-DR5 mass ratio of 1:100, after which the protein sample was loaded on a 5 mL 
HiTrap column (GE Healthcare), pre-equilibrated with the same buffer, for anion exchange 
chromatography. After elution at a NaCl concentration of 250 mM, the final DR5 protein 
consisted of 135 residues, including 3 N-ter residues (Gly1-Ala2-Met3) remaining from the 
TEV cleavage site.  Sample  purity  was checked  by  SDS-PAGE (15 % gels).  All  NMR 
samples were buffer exchanged with 20 mM Na2HPO4  pH 6.3 50 mM NaCl and either 10 
%  or  100  %  D2O,  using  PD-10  columns  (GE  Healthcare).  13C15N-DR5  sample 
concentration was made to 300 µM for assignment, using Amicon Ultra centrifugal 10 kD 
molecular weight cutoff filter units (Merck).
Mass spectroscopy
The average mass of intact DR5 was measured on a MALDI-TOFTOF mass spectrometer 
(Ultraflex III, Bruker) used in linear mode with sinapinic acid (Sigma-Aldrich) as a matrix  
[10 mg/mL solution in 50% acetonitrile in 0.1% aqueous trifluoroacetic acid (TFA)]. The 
dried  droplet  method  was  used  for  sample  loading  on  a  stainless  steel  target.  The  
instrument was calibrated using an external calibration with a mixture of four standard 
proteins: Insulin ([M+H]+average= 5734.51), Ubiquitin ([M+H]+average= 8565.76) , Cytochrom C 
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([M+H]+average= 12360.97), Myoglobin ([M+H]+average= 16952.30) (Bruker). Mass spectrometry 
(MS) study was performed to measure the average mass of the produced DR5 in order to  
assess  its  integrity.  This  analysis  demonstrated  the  presence  of  one  major  form 
corresponding to an average mass M=14998 Da (mean of four individual analysis).  The 
mass difference between the theoretical mass of the recombinant protein calculated from 
the sequence (15020.34 Da, taking into account all disulfide bonds in oxydized form) and 
the  experimental  mass  is  in  accordance  with  the  mass  tolerance  accepted  for  this 
measurement.
NMR spectroscopy
Spectra  were  acquired  at  303  K  on  a  Bruker  Avance  III  700  MHz  and  800  MHz 
spectrometers, equipped with a TXI triple resonance probe and cryoprobe, respectively. All  
data  were  processed  using  NMRPipe  (Delaglio  et  al,  1995)  and  analysed  by  using 
CCPNMR analysis 2.4 software (Skinner et al, 2016). Chemical shifts were referenced to 
TriMethylSilylPropanoic acid (TMSP) inside the samples (Wishart et al., 1995).  The  1H, 
1Hα,  13Cα,  1Hβ,  13Cβ  and  15N  backbone  resonances  of  DR5-ECD  were  derived  by 
sequence specific triple resonance 3D NMR spectra, namely HNCO, HN(CA)CO, HNCA, 
HN(CO)CA, HNCACB, CBCA(CO)NH, HNHA and HBHA(CO)NH. Side-chain resonance 
assignment was partially achieved by 3D NMR spectra, namely HC(C)H-TOCSY, (H)CCH-
TOCSY, H(C)CH-COSY, 15N-HSQC-NOESY (120 ms mixing time) and 15N-HSQC-TOCSY 
(60 ms mixing time), as well as by 2D NMR spectra in 100% D2O, namely aliphatic and 
aromatic 1H13C-HSQC, CBHD, CBHE, 1H1H-TOCSY and 1H1H-NOESY (Sattler et al, 1999).
Extents of assignments and data deposition
Analysis of the 3D sequential NMR experiments allowed us to assign 111 out of the 125  
expected  15N and  1H backbone resonances  (135  residues less  9  prolines  and the  N-
terminal  glycine).  The  backbone  assignment  is  nearly  complete  (89%),  except  for  14 
residues (A2, Q11, S40, D54, D61, C68, V76, T87, V88, C91, F96, R97, R106, K107). Ten 
peaks of the 1H15N HSQC spectrum however remain unassigned (Figure 1). The presence 
of  additional  peaks corresponding to  a minor  conformation was observed for  residues 
located in the N-terminal flexible region (S5, L7, I8, T9, D12, A14, A20, K24, S26, S27,  
S29) and for the tryptophan residue W125. Such minor conformations probably result from 
the surrounding proline residues in a cis conformation (P15, P21, P28 and P124). Slow 
conformational  exchange has also  been observed in  the  loop of  the  first  beta hairpin 
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(residues 41-44) and may arise from conformational heterogeneity of the disulphide bridge 
33-46 or protein oligomerization. We were able to extend the assignment up to 94, 93 and 
87% for the CO, Cα and Cβ chemical shifts, respectively. Hα, Cα, Cβ and CO chemical 
shift  values allowed us to assess the secondary structure of the protein in solution by  
using random coil values (Wang Y and Jardetsky O, 2002) and TALOS-N software (Yang 
S and Bax A, 2013). We found 8 of the 10 expected strands from crystal structures of DR5 
complexes and one additional  strand at the N-terminus (Figure 2),  namely  [residues 
32:33],  [37:39],  [46:48],  [54:55],  [69:70],  [75:79],  [86:91],  [116:120]  and 
[129:132]. An excellent agreement (Figure 3) has been found for the protein in solution 
with  the  X-ray  structures  of  DR5-ECD  bound  to  TRAIL  (1DOG.pdb,  1DU3.pdb  and 
1D4V.pdb),  to  FAB  fragments  (1ZA3,  2H9G,  3X3F,  4OD2  and  4N90)  and  to  the 
glycoprotein  UL141 (4I9X.pdb).   Most  of  the  resonances for  the  residues  of  the  third 
expected  -hairpin  [94:96]-[104:106] were not found in the 3D NMR spectra. All the 
unassigned residues seem to be clustered in the vicinity of the beta sheets ( : residue 
S40 ;   : D54 ;   : C68 ;   : V76,  : T87 and V88,   : F96 and R97 ;   : R106 and 
K107). These residues have not yet been assigned because peaks are missing or are too  
weak in intensity, probably arising from an excessive linebroadening beyond detection due 
to the presence of a conformational exchange on the intermediate millisecond timescale. 
The backbone and side-chain  1H,  13C and  15N chemical shift  values of DR5-ECD have 
been deposited at BioMagResBank under the accession number 27400.
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Figures with titles and legends
Figure 1:
Annotated 1H-15N HSQC spectrum of DR5-ECD
The  spectrum was  acquired  at  303K  on  a  Bruker  Avance  III  800  MHz spectrometer 
equipped with a 5 mm TXI  1H/13C/15N/2H cryoprobe. The 15N13C labelled protein was at a 
concentration of 300 M in 20 mM Na2HPO4 pH 6.3 50 mM NaCl in a mixture of 90% H2O/ 
10% D2O. The assignment of the peaks is indicated with the amino acid letter followed by 
the residue number. For clarity, a more detailed view of the central region is displayed  
separately in the top left corner of the spectrum. Unassigned peaks are labelled by the  
letters  na.  Assigned  peaks  corresponding  to  the  major  (65%)  and  minor  (35%) 
conformations for the same residue are respectively colored in black and cyan.
Figure 2:
Secondary structure of DR5-ECD in solution 
Assignment  of  secondary  structure  results  from  the  TALOS  prediction  based  on  the 
backbone resonance values. Chemical Shift Indexes (CSI) are calculated with chemical  
shift values of  13C,  13C,  13CO and 1H resonances. The ten strands of the consecutive 
five  beta  hairpins  are  sequentially  annotated  by  the  letter  beta  followed  by  the 
corresponding number.
Figure 3:
Comparison of DR5-ECD secondary structures in crystals and in solution
Alignment  of  the  DR5-ECD  protein  sequences  used  in  crystallography  and  NMR 
spectroscopy. Crystal structures of the DR5 bound to TRAIL or Fab fragments of anti-DR5 
antibodies are indicated on the left of the figure with the pdb code and the subunit. Visible  
and  missing  residues  are  respectively  in  black  and  in  grey.  Residues  in  the  beta 
conformation are in blue. Disulphide bridges are indicated. The three Cysteine Rich Domains 
(CRD) are represented schematically by rectangles in different colors.
9
Figure 1
10
Figure 2
11
12
Figure 3
13
